196 related articles for article (PubMed ID: 34601242)
1. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative.
Sasanejad P; Afshar Hezarkhani L; Arsang-Jang S; Tsivgoulis G; Ghoreishi A; Barlinn K; Rahmig J; Farhoudi M; Sadeghi Hokmabadi E; Borhani-Haghighi A; Sariaslani P; Sharifi-Razavi A; Ghandehari K; Khosravi A; Smith C; Nilanont Y; Akbari Y; Nguyen TN; Bersano A; Yassi N; Yoshimoto T; Lattanzi S; Gupta A; Zand R; Rafie S; Pourandokht Mousavian S; Reza Shahsavaripour M; Amini S; Kamenova SU; Kondybayeva A; Zhanuzakov M; Macri EM; Nobleza COS; Ruland S; Cervantes-Arslanian AM; Desai MJ; Ranta A; Moghadam Ahmadi A; Rostamihosseinkhani M; Foroughi R; Hooshmandi E; Akhoundi FH; Shuaib A; Liebeskind DS; Siegler J; Romano JG; Mayer SA; Bavarsad Shahripour R; Zamani B; Woolsey A; Fazli Y; Mojtaba K; Isaac CF; Biller J; Di Napoli M; Azarpazhooh MR
J Stroke Cerebrovasc Dis; 2021 Dec; 30(12):106121. PubMed ID: 34601242
[TBL] [Abstract][Full Text] [Related]
2. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y
Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
You S; Saxena A; Wang X; Tan W; Han Q; Cao Y; Liu CF
Stroke Vasc Neurol; 2018 Mar; 3(1):22-27. PubMed ID: 29600004
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study.
Zhu X; Wang N; Lin H; Zhang P; Chen L; Zhang M; Deng B; Wu T
J Stroke Cerebrovasc Dis; 2020 Feb; 29(2):104537. PubMed ID: 31806454
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Homeless Ischemic Stroke Patients Receiving Intravenous Thrombolysis in the United States.
Asaithambi G; Marino EH; Ho BM; Tipps ME
J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105862. PubMed ID: 34034124
[TBL] [Abstract][Full Text] [Related]
6. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
[TBL] [Abstract][Full Text] [Related]
7. Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy.
Abbas A; Hamad AA; El Din Moawad MH; Ewis DK; Youssef RA; Hamouda H; Hassan MA; Aladawi M; Elfil M; Meshref M; Al-Mufti F
J Stroke Cerebrovasc Dis; 2024 Jul; 33(7):107704. PubMed ID: 38561167
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.
Sharma VK; Tsivgoulis G; Tan JH; Wong LY; Ong BK; Chan BP; Teoh HL
J Stroke Cerebrovasc Dis; 2010; 19(6):424-30. PubMed ID: 20554224
[TBL] [Abstract][Full Text] [Related]
9. Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
Dong Y; Cao W; Cheng X; Fang K; Wu F; Yang L; Xie Y; Dong Q
Stroke Vasc Neurol; 2016 Sep; 1(3):115-121. PubMed ID: 28959472
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
11. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
12. Target: Stroke Was Associated With Faster Intravenous Thrombolysis and Improved One-Year Outcomes for Acute Ischemic Stroke in Medicare Beneficiaries.
Man S; Xian Y; Holmes DN; Matsouaka RA; Saver JL; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2020 Dec; 13(12):e007150. PubMed ID: 33302714
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the Telestroke Drip-And-Stay Model: A Systematic Review and Meta-Analysis.
Waseem H; Salih YA; Burney CP; Abel MA; Riblet N; Kim A; Robbins N
J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105638. PubMed ID: 33540336
[TBL] [Abstract][Full Text] [Related]
14. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
[TBL] [Abstract][Full Text] [Related]
15. Mean Platelet Volume is a Prognostic Marker in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.
Dourado Sotero F; Calçada A; Aguiar de Sousa D; Dias M; Fonseca AC; Pinho E Melo T; Canhão P
J Stroke Cerebrovasc Dis; 2021 Jun; 30(6):105718. PubMed ID: 33838517
[TBL] [Abstract][Full Text] [Related]
16. Stroke Care Trends During COVID-19 Pandemic in Zanjan Province, Iran. From the CASCADE Initiative: Statistical Analysis Plan and Preliminary Results.
Ghoreishi A; Arsang-Jang S; Sabaa-Ayoun Z; Yassi N; Sylaja PN; Akbari Y; Divani AA; Biller J; Phan T; Steinwender S; Silver B; Zand R; Basri HB; Iqbal OM; Ranta A; Ruland S; Macri E; Ma H; Nguyen TN; Abootalebi S; Gupta A; Alet M; Lattanzi S; Desai M; Gagliardi RJ; Girotra T; Inoue M; Yoshimoto T; Isaac CF; Mayer SA; Morovatdar N; Nilanont Y; Nobleza COS; Saber H; Kamenova S; Kondybayeva A; Krupinski J; Siegler JE; Stranges S; Torbey MT; Yorio D; Zurrú MC; Rubinos CA; Shahripour RB; Borhani-Haghighi A; Napoli MD; Azarpazhooh MR
J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105321. PubMed ID: 33069086
[TBL] [Abstract][Full Text] [Related]
17. Disparities between Asian and Non-Asian Thrombolyzed Acute Ischemic Stroke Patients in the Enhanced Control of Hypertension and Thrombolysis Stroke Trial.
Chen C; Wang X; Chen X; Ouyang M; Sun L; Arima H; Robinson T; Lindley RI; Chalmers J; Li G; Song L; Anderson CS;
Cerebrovasc Dis; 2021; 50(5):560-566. PubMed ID: 34153968
[TBL] [Abstract][Full Text] [Related]
18. Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA.
Joo H; Wang G; George MG
Stroke Vasc Neurol; 2016 Mar; 1(1):8-15. PubMed ID: 27547449
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Thrombolysis for Acute Ischemic Stroke due to Cervical Internal Carotid Artery Occlusion.
Yeo LL; Kong WY; Paliwal P; Teoh HL; Seet RC; Soon D; Rathakrishnan R; Ong V; Lee TH; Wong HF; Chan BP; Leow WK; Yuan C; Ting E; Gopinathan A; Tan BY; Sharma VK
J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2423-9. PubMed ID: 27344361
[TBL] [Abstract][Full Text] [Related]
20. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.
Masrur S; Abdullah AR; Smith EE; Hidalgo R; El-Ghandour A; Rordorf G; Schwamm LH
J Stroke Cerebrovasc Dis; 2011; 20(2):124-30. PubMed ID: 20598579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
